ESR1 and breast carcinoma: ESR1 ligand-binding domain (LBD) mutations that induce endocrine therapy (ET) resistance in breast cancer (BC) were first reported almost two decades ago [1–4] and novel developments of sensitive technologies such as next-generation sequencing (NGS) confirmed that ESR1 LBD mutations act as drivers of ET resistance [5–8].